These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34474072)

  • 1. Extremely short bioavailability and fast pharmacodynamic effects of pMHC-based nanomedicines.
    Yang Y; Ellestad KK; Singha S; Uddin MM; Clarke R; Mondal D; Garabatos N; Solé P; Fandos C; Serra P; Santamaria P
    J Control Release; 2021 Oct; 338():557-570. PubMed ID: 34474072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide-MHC-Based Nanomedicines for the Treatment of Autoimmunity: Engineering, Mechanisms, and Diseases.
    Serra P; Santamaria P
    Front Immunol; 2020; 11():621774. PubMed ID: 33574822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of a broad spectrum of liver autoimmune pathologies by single peptide-MHC-based nanomedicines.
    Umeshappa CS; Singha S; Blanco J; Shao K; Nanjundappa RH; Yamanouchi J; Parés A; Serra P; Yang Y; Santamaria P
    Nat Commun; 2019 May; 10(1):2150. PubMed ID: 31089130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide-MHC-based nanomedicines for autoimmunity function as T-cell receptor microclustering devices.
    Singha S; Shao K; Yang Y; Clemente-Casares X; Solé P; Clemente A; Blanco J; Dai Q; Song F; Liu SW; Yamanouchi J; Umeshappa CS; Nanjundappa RH; Detampel P; Amrein M; Fandos C; Tanguay R; Newbigging S; Serra P; Khadra A; Chan WCW; Santamaria P
    Nat Nanotechnol; 2017 Jul; 12(7):701-710. PubMed ID: 28436959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptional re-programming of insulin B-chain epitope-specific T-follicular helper cells into anti-diabetogenic T-regulatory type-1 cells.
    Solé P; Parras D; Yamanouchi J; Garnica J; Garabatos N; Moro J; Montaño J; Mondal D; Fandos C; Yang Y; Serra P; Santamaria P
    Front Immunol; 2023; 14():1177722. PubMed ID: 37153608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantifying immunoregulation by autoantigen-specific T-regulatory type 1 cells in mice with simultaneous hepatic and extra-hepatic autoimmune disorders.
    Jamaleddine H; Santamaria P; Khadra A
    Immunology; 2020 Nov; 161(3):209-229. PubMed ID: 32687611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantifying the importance of pMHC valency, total pMHC dose and frequency on nanoparticle therapeutic efficacy.
    Sugarman J; Tsai S; Santamaria P; Khadra A
    Immunol Cell Biol; 2013 May; 91(5):350-9. PubMed ID: 23528729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanding antigen-specific regulatory networks to treat autoimmunity.
    Clemente-Casares X; Blanco J; Ambalavanan P; Yamanouchi J; Singha S; Fandos C; Tsai S; Wang J; Garabatos N; Izquierdo C; Agrawal S; Keough MB; Yong VW; James E; Moore A; Yang Y; Stratmann T; Serra P; Santamaria P
    Nature; 2016 Feb; 530(7591):434-40. PubMed ID: 26886799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re-Programming Autoreactive T Cells Into T-Regulatory Type 1 Cells for the Treatment of Autoimmunity.
    Solé P; Santamaria P
    Front Immunol; 2021; 12():684240. PubMed ID: 34335585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoparticle-mediated targeting of autoantigen peptide to cross-presenting liver sinusoidal endothelial cells protects from CD8 T-cell-driven autoimmune cholangitis.
    Carambia A; Gottwick C; Schwinge D; Stein S; Digigow R; Şeleci M; Mungalpara D; Heine M; Schuran FA; Corban C; Lohse AW; Schramm C; Heeren J; Herkel J
    Immunology; 2021 Apr; 162(4):452-463. PubMed ID: 33346377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigen-specific nanomedicines for the treatment of autoimmune disease: target cell types, mechanisms and outcomes.
    Yang Y; Santamaria P
    Curr Opin Biotechnol; 2022 Apr; 74():285-292. PubMed ID: 35007990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoparticle-based autoantigen delivery to Treg-inducing liver sinusoidal endothelial cells enables control of autoimmunity in mice.
    Carambia A; Freund B; Schwinge D; Bruns OT; Salmen SC; Ittrich H; Reimer R; Heine M; Huber S; Waurisch C; Eychmüller A; Wraith DC; Korn T; Nielsen P; Weller H; Schramm C; Lüth S; Lohse AW; Heeren J; Herkel J
    J Hepatol; 2015 Jun; 62(6):1349-56. PubMed ID: 25617499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On how monospecific memory-like autoregulatory CD8+ T cells can blunt diabetogenic autoimmunity: a computational approach.
    Khadra A; Tsai S; Santamaria P; Edelstein-Keshet L
    J Immunol; 2010 Nov; 185(10):5962-72. PubMed ID: 20962260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T cell receptor binding kinetics required for T cell activation depend on the density of cognate ligand on the antigen-presenting cell.
    González PA; Carreño LJ; Coombs D; Mora JE; Palmieri E; Goldstein B; Nathenson SG; Kalergis AM
    Proc Natl Acad Sci U S A; 2005 Mar; 102(13):4824-9. PubMed ID: 15772168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ubiquitous antigen-specific T regulatory type 1 cells variably suppress hepatic and extrahepatic autoimmunity.
    Umeshappa CS; Mbongue J; Singha S; Mohapatra S; Yamanouchi J; Lee JA; Nanjundappa RH; Shao K; Christen U; Yang Y; Ellestad KK; Santamaria P
    J Clin Invest; 2020 Apr; 130(4):1823-1829. PubMed ID: 32125290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nano-Bio Interactions in Cancer: From Therapeutics Delivery to Early Detection.
    Liu Y; Wang J; Xiong Q; Hornburg D; Tao W; Farokhzad OC
    Acc Chem Res; 2021 Jan; 54(2):291-301. PubMed ID: 33180454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in physiologically based pharmacokinetic and pharmacodynamic models for anticancer nanomedicines.
    Byun JH; Han DG; Cho HJ; Yoon IS; Jung IH
    Arch Pharm Res; 2020 Jan; 43(1):80-99. PubMed ID: 31975317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural basis for self-recognition by autoimmune T-cell receptors.
    Yin Y; Li Y; Mariuzza RA
    Immunol Rev; 2012 Nov; 250(1):32-48. PubMed ID: 23046121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of nanomedicines for the treatment of autoimmune disease: From vehicles for drug delivery to inducers of bystander immunoregulation.
    Yang Y; Santamaria P
    Adv Drug Deliv Rev; 2021 Sep; 176():113898. PubMed ID: 34314782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advantages and challenges in nanomedicines for chronic liver diseases: A hepatologist's perspectives.
    Ezhilarasan D
    Eur J Pharmacol; 2021 Feb; 893():173832. PubMed ID: 33359144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.